Sign In
Buy ILMN
$168.06
-2.87 (-1.68%)
At Close: Jun 04, 2026
Illumina (ILMN) Misses Q4 Earnings Estimates
06:49pm, Tuesday, 07'th Feb 2023
Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DNA-Reading Giant Illumina Topples On Wide Profit Miss
04:13pm, Tuesday, 07'th Feb 2023
Illumina beat sales estimates, but profit came in light during the fourth quarter. That led ILMN stock to fall in late action Tuesday.
Illumina, Pacific Biosciences, And Oxford Nanopore Market Position Comparison
02:12am, Monday, 06'th Feb 2023
The gene sequencing market is ripe for disruption. ILMN suffers from multiple strategic setbacks that will likely impact margins for years.
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
11:46am, Tuesday, 31'st Jan 2023
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investing in Cancer Stocks
10:43am, Monday, 30'th Jan 2023
Learn about some of the leading cancer stocks in the U.S stock market this year.
Illumina CEO on gene sequencing: 'We are trying to unravel the biology of diseases'
03:33pm, Friday, 20'th Jan 2023
Illumina CEO Francis deSouza spoke with Yahoo Finance's Julie Hyman about the developments in genomic sequencing, testing, and healthcare, and the part Illumina is playing to make this more accessible
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
09:02am, Thursday, 19'th Jan 2023
Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.
Illumina CEO: Genomics in children's hospitals will be the biggest part of the market
08:42am, Thursday, 19'th Jan 2023
Francis Desouza, Illumina CEO and Disney board member, joins 'Squawk Box' to discuss the future of gene sequencing and what Illumina is doing, the promise behind Illumina's GRAIL and more.
What's Happening With Illumina Stock?
07:00am, Friday, 13'th Jan 2023
Illumina stock (NASDAQ: ILMN) saw a significant 53% fall in the last twelve months, underperforming the broader S&P500 index, down 16%.
Illumina CEO on Earnings Outlook, Buying Grail
04:53pm, Wednesday, 11'th Jan 2023
Illumina Inc. CEO Francis deSouza talks about earnings, the profit outlook and buying Grail. He speaks to Bloomberg's Kailey Leinz at the JPMorgan Healthcare Conference.
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
04:05pm, Tuesday, 10'th Jan 2023
SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, F
Illumina (ILMN), Nashville Biosciences Partner With Amgen
12:02pm, Tuesday, 10'th Jan 2023
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.
Biotech's Illumina stock tumbles on weaker-than-expected profit outlook
10:46am, Tuesday, 10'th Jan 2023
Yahoo Finance Live anchors discuss the decline in stock for Illumina after the company issued weaker-than-expected guidance for 2023.
Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues
10:19am, Tuesday, 10'th Jan 2023
Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023. The post Illumina's Woes Mount As Guidance Lags And Grail Co
Illumina's stock falls 10% on ‘more cautious outlook' for 2023
09:04am, Tuesday, 10'th Jan 2023
Shares of Illumina Inc. ILMN, +2.69% tumbled about 10% in premarket trading on Tuesday, the day after the company said it expects lower-than-expected earnings per share of of $1.25 to $1.50 in 2023. T
